Satsuma Pharmaceuticals, Inc. Banner Image

Satsuma Pharmaceuticals, Inc.

  • Ticker STSA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Satsuma Pharmaceuticals, Inc. Logo Image
  • 11-50 Employees
  • Based in South San Francisco, California
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101. STS101 is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. In developingMore STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, simple-to-use, non-injectable DHE product that can be rapidly self-administered in a matter of seconds.
4.8 / 5.0 (134)

Satsuma Pharmaceuticals, Inc. reports have an aggregate usefulness score of 4.8 based on 134 reviews.

Satsuma Pharmaceuticals, Inc.

Most Recent Annual Report

Satsuma Pharmaceuticals, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Satsuma Pharmaceuticals, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!